These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 27202812)

  • 1. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.
    Haro JM; Suarez D; Novick D; Brown J; Usall J; Naber D;
    Eur Neuropsychopharmacol; 2007 Mar; 17(4):235-44. PubMed ID: 17137759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.
    Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the findings from the European SOHO study.
    Suarez D; Haro JM
    Expert Rev Neurother; 2008 Jun; 8(6):873-80. PubMed ID: 18505352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: results after 1 year from a prospective, observational study (IC-SOHO).
    Treuer T; Anders M; Bitter I; Dobre G; Pecenak J; Dyachkova Y; Harrison G; O'Mahoney J
    Int J Psychiatry Clin Pract; 2006; 10(2):78-90. PubMed ID: 24940957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
    Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
    J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L; Czobor P; Bitter I
    Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
    Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair).
    Bahceciler NN; Babayigit Hocaoglu A; Galip N
    Expert Rev Vaccines; 2014 Dec; 13(12):1427-38. PubMed ID: 25345538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Lee P; Eung Kim C; Yoon Kim C; Lin WW; Habil H; Dyachkova Y; Mcbride M; Dossenbach M
    Int J Psychiatry Clin Pract; 2008; 12(3):215-27. PubMed ID: 24931661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.
    Hong J; Novick D; Brugnoli R; Bertsch J; Haro JM
    Hum Psychopharmacol; 2013 Sep; 28(5):438-46. PubMed ID: 23775950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics?
    Castberg I; Westin AA; Spigset O
    J Clin Psychopharmacol; 2009 Oct; 29(5):415-20. PubMed ID: 19745639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder.
    Novick D; Montgomery W; Treuer T; Koyanagi A; Aguado J; Kraemer S; Haro JM
    Patient Prefer Adherence; 2017; 11():1019-1025. PubMed ID: 28652711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness in Terms of Treatment Discontinuation of Orodispersable Versus. Standard Oral Olanzapine Tablets in Non-Adherent Patients: Results from a 1-Year European Outpatient Observational Study.
    Novick D; Montgomery W; Treuer T; Aguado J; Kraemer S; Haro JM
    Value Health; 2014 Nov; 17(7):A766. PubMed ID: 27202812
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.